---
title: "Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)"
date: "2025-09-11T04:00:00.000Z"
publishedDate: "11 septembre 2025"
summary: "Conditions : Achondroplasia Interventions : Drug: Infigratinib is provided as a single dose of minitablets for oral administration; Drug: Infigratinib is provided as sprinkle capsules for daily oral administration; Drug: Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration; Drug: Infigratinib is provided as sprinkle capsules for daily oral administration Sponsors : QED Therapeutics, Inc., a Bridgebio company Not yet recruiting"
importance: ""
sourceUrl: "https://clinicaltrials.gov/study/NCT07169279?term=interventional+radiology&aggFilters=status%3A"
tags: ["France", "Actualité", "ClinicalTrials.gov — ta recherche"]
permalink: "/papers/2025-09-11-interventional-study-of-infigratinib-in-children-less-3-years-old-with-achondroplasia-ach"
imageUrl: ""
imageCredit: ""
---

## L’essentiel

Conditions : Achondroplasia Interventions : Drug: Infigratinib is provided as a single dose of minitablets for oral administration; Drug: Infigratinib is provided as sprinkle capsules for daily oral administration; Drug: Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration; Drug: Infigratinib is provided as sprinkle capsules for daily oral administration Sponsors : QED Therapeutics, Inc., a Bridgebio company Not yet recruiting

## Lien source

https://clinicaltrials.gov/study/NCT07169279?term=interventional+radiology&aggFilters=status%3A
